ZYDUSLIFEZydus Lifesciences Ltd.
Zydus Lifesciences completes acquisition of Sterling Biotech's API unit
- Mergers & acquisitions
- Pharmaceuticals
Reviewed byKeshav SehgalBlacklitt Research
Zydus Lifesciences (NSE: ZYDUSLIFE) has completed the acquisition of the API business of Sterling Biotech Limited, it said in a filing on 02 Nov 2026. The closing followed the fulfilment of conditions precedent and closing date adjustments under a Business Transfer Agreement dated 17 Sep 2024.
What was acquired and how it closed
Zydus Lifesciences has completed the acquisition of the API business of Sterling Biotech Limited. API stands for active pharmaceutical ingredient, the substance in a medicine that produces its effect.
The Business Transfer Agreement between Zydus Lifesciences and Sterling Biotech Limited is dated 17 Sep 2024. The closing followed the completion of conditions precedent and closing date adjustments set out in that agreement.
The filing is an update to an earlier intimation about the same acquisition, and it reports only that the deal has closed.
What the acquisition means for Zydus Lifesciences' shareholders
The filing records a completed purchase of an API business but gives no size for it, so its scale against the company cannot be measured from the filing. Not stated: the consideration paid, the date the deal closed, the revenue or profit of the business acquired, and the effect on the company's results.
The filing names no next dated step.
At a glance
| Item | Detail |
|---|---|
| Business acquired | API business of Sterling Biotech Limited |
| Seller | Sterling Biotech Limited |
| Agreement | Business Transfer Agreement dated 17 Sep 2024 |
| Filing date | 02 Nov 2026 |
| Consideration | Not stated in the filing |
| Closing date | Not stated in the filing |
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
